Elderly Patients

by

Understanding the appropriate dosing of amlodipine in special populations is crucial for optimizing therapeutic outcomes and minimizing adverse effects. This article provides evidence-based recommendations tailored for specific groups, including the elderly, patients with hepatic impairment, and those with renal dysfunction.

Elderly Patients

In elderly patients, age-related physiological changes can affect drug metabolism and sensitivity. It is recommended to start with a lower initial dose of 5 mg once daily. Titration should be cautious, with incremental increases of 2.5 mg, monitoring blood pressure response and tolerability.

Considerations include:

  • Assess renal and hepatic function before initiation.
  • Monitor for signs of hypotension and edema.
  • Adjust doses accordingly, not exceeding 10 mg daily unless necessary.

Patients with Hepatic Impairment

Hepatic impairment can reduce drug clearance, leading to increased plasma concentrations. For patients with mild to moderate hepatic dysfunction, initiate therapy at 5 mg once daily. Dose escalation should be cautious, with careful monitoring for adverse effects.

For severe hepatic impairment, consider starting at 2.5 mg daily, with close observation. Dose adjustments should be individualized based on response and tolerability.

Patients with Renal Dysfunction

Amlodipine is primarily metabolized by the liver, and renal impairment has minimal effect on its pharmacokinetics. However, in patients with severe renal disease, monitor blood pressure and for signs of fluid retention.

Initial dosing remains at 5 mg once daily. Titration should be performed based on therapeutic response, with adjustments as needed, up to a maximum of 10 mg daily.

General Recommendations

Across all populations, consider the following:

  • Start at the lowest effective dose.
  • Gradually titrate based on blood pressure response and side effects.
  • Regularly monitor blood pressure, heart rate, and adverse effects.
  • Adjust dosing in response to clinical changes and laboratory findings.

In conclusion, personalized dosing of amlodipine in special populations enhances safety and efficacy. Clinicians should consider individual patient factors and adhere to these recommendations for optimal management.